GO-203 is primarily used in cancer research due to its ability to inhibit the oncogenic protein MUC1*. This compound specifically targets the interaction between MUC1* and key signaling molecules involved in tumor cell survival and proliferation. It has shown potential in inducing apoptosis in cancer cells, particularly in hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma. GO-203 works by penetrating cells and disrupting the MUC1*-mediated activation of survival pathways like NF-κB and PI3K/AKT, thereby sensitizing tumor cells to chemotherapy and reducing drug resistance. Its application is mainly in preclinical studies as a targeted therapeutic agent, with ongoing research exploring its efficacy in combination therapies and solid tumors.